NCT02798406
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects treatment 2 completed NCT06496971
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients treatment 3 not_yet_recruiting NCT03911388
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors treatment 1 active_not_recruiting NCT02745756
A Combined Cell Therapy Approach to the Treatment of Neuroblastoma No drug interventions treatment 1 withdrawn NCT06329570
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM) treatment 1 / 2 not_yet_recruiting NCT04446416
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients treatment Not Available completed NCT04862780
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC treatment 1 / 2 active_not_recruiting NCT03109301
Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST) treatment 2 withdrawn NCT04222972
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) treatment 3 active_not_recruiting NCT04697446
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC No drug interventions Not Available Not Available unknown_status NCT04388033
Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients. treatment 1 / 2 unknown_status NCT01579253
Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients No drug interventions Not Available Not Available unknown_status NCT03037385
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors treatment 1 / 2 completed NCT03626896
Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients No drug interventions device_feasibility Not Available completed NCT04949282
Spanish Series of Patients Treated With the Radionuclide Lutetium177 Not Available Not Available recruiting NCT05153408
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC treatment 1 terminated NCT05592743
Vorasidenib Expanded Access Program Not Available Not Available available